Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Yanji Pharmaceutical, received a drug registration certificate for Terbutaline Sulfate Nebuliser Solution, enhancing the company's product portfolio and core competitiveness [1][3]. Drug Registration Details - The drug is classified as a chemical drug of category 4, with a specification of 2ml:5mg and a shelf life of 24 months [1][2]. - The drug is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [3]. Impact on the Company - The acquisition of the drug registration certificate is expected to improve the company's product structure and diversify its product offerings, creating favorable conditions for steady development [3]. - The company plans to comply with relevant laws and regulations while conducting production and sales of the new product, although the sales performance may be influenced by market conditions [3].

Group 1 - The core point of the article is that Jilin Aodong has received a drug registration certificate for "Sulfuric Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of September 5, indicating a significant regulatory approval for the company's product [2] - The product is expected to enhance the company's portfolio in the pharmaceutical sector, particularly in respiratory treatments [2] - This approval may lead to increased market opportunities and potential revenue growth for Jilin Aodong [2]

Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Group 1 - Jilin Aodong Pharmaceutical Group's subsidiary received a drug registration certificate for "Sulfuric Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration [1] - As of January to June 2025, Jilin Aodong's revenue composition is as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - Jilin Aodong's market capitalization is currently 23 billion yuan [1]

Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulization Solution" [1] - The indication for the sulfate terbutaline nebulization solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulized Inhalation Solution," indicating a significant development in its product portfolio [1]. Group 1 - The newly approved product is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1].

Core Viewpoint - Jilin Aodong announced that its subsidiary Yanji Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for "Sulfuric Terbutaline Nebulized Inhalation Solution," which is used to relieve bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The drug registration certificate enhances the company's product structure [1] - The approval enriches the variety of products offered by the company [1] - This development strengthens the company's core competitiveness in the pharmaceutical industry [1]

Core Viewpoint - Jilin Aodong announced that its subsidiary Yanji Pharmaceutical has received the "Drug Registration Certificate" for "Sulfate Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration, which is used to relieve bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The approval of the drug registration certificate enhances the company's product structure [1] - The new product enriches the variety of the company's offerings [1] - This development strengthens the company's core competitiveness [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (referred to as "Yanji Pharmaceutical"), has received the "Drug Registration Certificate" for "Sulbutamol Sulfate Nebulized Inhalation Solution" from the National Medical Products Administration [1] Group 1 - The indication for Sulbutamol Sulfate Nebulized Inhalation Solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group's subsidiary has received a drug registration certificate for "Salbutamol Sulfate Nebulization Solution" from the National Medical Products Administration, indicating a significant development in the company's product offerings [1] Company Summary - Jilin Aodong Pharmaceutical Group's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., has been granted a registration certificate for a new medication [1] - The newly approved medication is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1]